Literature DB >> 19204737

Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG.

B F McBride1, T Yang, D M Roden.   

Abstract

The drug efflux pump P-glycoprotein possesses two common and often linked polymorphisms that result in variable drug action. G2677T results in A893S, whereas C3435T is synonymous and has been reported to alter protein folding. We tested the effect of these MDR1 variants on Human Ether-Related A Go-Go (HERG) block by ibutilide in CHO cells 48 h following transient transfection with an IRES-dsRed vector containing MDR1, G2677T MDR1, G2677T/C3435T MDR1 or an empty bicistronic site and an IRES-GFP vector containing HERG (KCNH2). Cotransfection of MDR1 variants had no effect on I(Kr) amplitude at baseline. Cells cotransfected with MDR1-G2677T showed resistance to ibutilide vs HERG alone (IC(50): 105.3+/-1.42 nM vs 27.4+/-2.5 nM; P<0.0001), consistent with the idea that A893S attenuates I(Kr) block by enhancing drug efflux and thus reducing the drug available to interact with the channel binding site. However, G2677T/C3435T cells showed ibutilide sensitivity similar to cells expressing HERG alone (IC(50): 22.2+/-0.9 nM). Immunostaining showed that the C3435T variant did not traffic to the cell surface. Coculture with fexofenadine(1 microM), an MDR1 substrate known to rescue misfolding in other membrane proteins, restored cell surface expression of MDR1 G2677T/C3435T and restored resistance to block HERG by ibutilide 200 nM (98.5+/-0.98% vs 42.3+/-2.2%, P<0.001). The non-synonymous MDR1 variant G2677 T (A893S) confers resistance to ibutilide block of I(Kr), which is mitigated by the C3435T polymorphism through reduced protein expression, an effect that can be restored by coculture with fexofenadine. These data identify ibutilide as an MDR1 substrate and further support the concept that variable drug transport function can modulate the action of HERG blockers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19204737      PMCID: PMC3775644          DOI: 10.1038/tpj.2009.1

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  44 in total

Review 1.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology.

Authors:  W Haverkamp; G Breithardt; A J Camm; M J Janse; M R Rosen; C Antzelevitch; D Escande; M Franz; M Malik; A Moss; R Shah
Journal:  Eur Heart J       Date:  2000-08       Impact factor: 29.983

2.  Potassium channel receptor site for the inactivation gate and quaternary amine inhibitors.

Authors:  M Zhou; J H Morais-Cabral; S Mann; R MacKinnon
Journal:  Nature       Date:  2001-06-07       Impact factor: 49.962

3.  Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients.

Authors:  Nada Bozina; Martina Rojnic Kuzman; Vesna Medved; Nikolina Jovanovic; Jadranka Sertic; Ljubomir Hotujac
Journal:  J Psychiatr Res       Date:  2006-11-20       Impact factor: 4.791

4.  A "silent" polymorphism in the MDR1 gene changes substrate specificity.

Authors:  Chava Kimchi-Sarfaty; Jung Mi Oh; In-Wha Kim; Zuben E Sauna; Anna Maria Calcagno; Suresh V Ambudkar; Michael M Gottesman
Journal:  Science       Date:  2006-12-21       Impact factor: 47.728

5.  Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome.

Authors:  W Shimizu; C Antzelevitch
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

6.  Effects of experimental heart failure on atrial cellular and ionic electrophysiology.

Authors:  D Li; P Melnyk; J Feng; Z Wang; K Petrecca; A Shrier; S Nattel
Journal:  Circulation       Date:  2000-06-06       Impact factor: 29.690

7.  A structural basis for drug-induced long QT syndrome.

Authors:  J S Mitcheson; J Chen; M Lin; C Culberson; M C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

8.  Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias.

Authors:  C Napolitano; P J Schwartz; A M Brown; E Ronchetti; L Bianchi; A Pinnavaia; G Acquaro; S G Priori
Journal:  J Cardiovasc Electrophysiol       Date:  2000-06

9.  Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects.

Authors:  Kyoung-Ah Kim; Pil-Whan Park; Ji-Young Park
Journal:  Br J Clin Pharmacol       Date:  2006-07-21       Impact factor: 4.335

10.  1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation.

Authors:  Laure Elens; Arnaud Capron; Valérie Van Kerckhove; Jan Lerut; Michel Mourad; Dominique Lison; Pierre Wallemacq; Vincent Haufroid
Journal:  Pharmacogenet Genomics       Date:  2007-10       Impact factor: 2.089

View more
  7 in total

Review 1.  Drug- and non-drug-associated QT interval prolongation.

Authors:  Charlotte van Noord; Mark Eijgelsheim; Bruno H Ch Stricker
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

2.  Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1.

Authors:  Tao Yang; Brian F McBride; Brenda F Leake; Richard B Kim; Dan M Roden
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 3.  Thorough QT Studies: Questions and Quandaries.

Authors:  Marek Malik; Christine E Garnett; Joanne Zhang
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

Review 4.  Pharmacogenetics of Potassium Channel Blockers.

Authors:  Dan M Roden
Journal:  Card Electrophysiol Clin       Date:  2016-06

Review 5.  Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk.

Authors:  András Varró; István Baczkó
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

6.  Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects.

Authors:  Henry P Parkman; Michael R Jacobs; Anurag Mishra; Jessica A Hurdle; Priyanka Sachdeva; John P Gaughan; Evgeny Krynetskiy
Journal:  Dig Dis Sci       Date:  2010-11-10       Impact factor: 3.199

7.  Intracellular Binding of Terfenadine Competes with Its Access to Pancreatic ß-cell ATP-Sensitive K+ Channels and Human ether-à-go-go-Related Gene Channels.

Authors:  Bernd J Zünkler; Maria Wos-Maganga; Stefanie Bohnet; Anne Kleinau; Detlef Manns; Shivani Chatterjee
Journal:  J Membr Biol       Date:  2022-06-28       Impact factor: 1.843

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.